Safety and Efficacy of Ga-68-Αvβ3 IAC Positron Emission Tomography (PET/CT) for Diagnosis and Clinical Management in Angiogenic Breast Cancer Patients.

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 May 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs AIP-301 (Primary)
Indications Breast cancer; Gastric cancer; Lung cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions
Acronyms Shiva; The SHIVA Study
Sponsors Advanced Imaging Projects

16 May 2024 Planned End Date changed from 30 Aug 2024 to 30 Aug 2025.
16 May 2024 Planned primary completion date changed from 30 Aug 2024 to 30 Aug 2025.
16 May 2024 Planned initiation date changed from 30 Aug 2022 to 30 Aug 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com